Cannabinoid agonists in the treatment of blepharospasm - A case report study

Neuroendocrinology Letters

Volumn 25, Issue 1-2, 2004, Pages 45-48

  Gauter, Benjamin ^a,b   Rukwied, Roman ^a   Konrad, Christoph ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

Author keywords

Blepharospasm; Botulinum toxin; Cannabinoid; CB1 receptor; Dronabinol; Dystonia

Indexed keywords

BOTULINUM TOXIN; CANNABINOID 1 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE 2 RECEPTOR; DRONABINOL; NEUROMUSCULAR BLOCKING AGENT; TRANQUILIZER; ANALGESIC AGENT; BOTULINUM TOXIN A; TETRAHYDROCANNABINOL;

ARTICLE; BLEPHAROSPASM; CLINICAL FEATURE; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; GABAERGIC SYSTEM; HUMAN; MOTOR CONTROL; NEUROTRANSMISSION; CASE REPORT; DIET THERAPY; DYSTONIA; FEMALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ANALGESICS, NON-NARCOTIC; BLEPHAROSPASM; BOTULINUM TOXIN TYPE A; DYSTONIC DISORDERS; FEMALE; HUMANS; MIDDLE AGED; TETRAHYDROCANNABINOL; TREATMENT OUTCOME;

EID: 3242806761     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Haslett M. Blepharospasm: Recent advances. Neurology 2002; 59:1306-1312.
2. Defazio G, F Brancati, EM Valente, V Caputo, A Pizzuti, D Martino, G Abbruzzese, P Livrea, A Berardelti, and B Dallapiccola. Familiar blepharospasm is inherited as an autosomal dominant trait and relates to a novel unassigned gene. Mov Disord 2003; 18: 207-212.
3. Horwath-Winter JJ, Bergloeff, I Floegel, E M Haller-Schober, and O Schmut. Botulinum toxin. A treatment in patients suffering from blepharospasm and dry eye. Br J Ophthalmol 2003; 87: 54-56.
4. Arevalo-Martin A, Vela JM, Molina-Holgado E, J Borrell, and C Guaza. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003; 23:2511-2516.
5. Baker, D and G Pryce. The therapeutic potential of cannabis in multiple sclerosis. Expert Opin Investig Drugs 2003; 12: 561-567.
6. Hermann H, Marsicano G, and Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002; 109:451-460.
7. Giuffrida A, Parsons LH, Kerr TM, Rodriguez DF, Navarro M, and Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999; 2:358-363.
8. Clermont-Gnamien S, Atlani S, Attal N, Le Mercier F, Guirimand F and Brasseur L. The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain. Presse Med 2002; 31:1840-1845.
9. Croxford JL. Therapeutic potential of cannabinoids in CNS disease CNS Drugs 2003; 17:179-202.
10. Gonzales-Rosales F and Walsh D. Intractable Nausea and Vomitting due to Gastrointestinal Mucosal Metastases Relieved by Tetrahydrocannabinol (Dronabinol). Journal of Pain and Symptom Management 1997; 14:311-314.
11. Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries K and Evans TG. Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993; 27:827-831.
12. De Vries TJ, Y Shaham, JR Homberg, H Crombag, K Schuurman, J Dieben, L J Vanderschuren, and A N Schoffelmeer. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 2001; 7: 1151-1154.
13. Gilio F, Curra A, Inghilleri M, Lorenzano C, Suppa A, Manfredi M and Berardelli A. Abnormalities of motor cortex excitability preceding movement in patients with dystonia. Brain 2003; 126: 1745-1754.
14. Kanovsky P. Dystonia: a disorder of motor programming or motor execution? Mov Disord 2002; 17:1143-1147.
15. Baker RS, Andersen AH, Morecraft RJ, and Smith CD. A functional magnetic resonance imaging study in patients with benign essential blepharospasm. J Neuroophthalmol 2003; 23:11-15.
16. Cif L, El Fertit H, Vayssiere N, Hemm S, Hardouin E, Gannau A, Tuffery S and Coubes P. Treatment of dystonic syndromes by chronic electrical stimulation of the internal globus pallidus. J Neurosurg Sci 2003; 47:52-55.
17. Bronte-Stewart, H. Surgical therapy for dystonia. Curr Neurol Neurosci Rep 2003; 3:296-305.
18. Cohen-Gadol AA, Ahlskog JE, Matsumoto JY, Swenson MA, McClelland RL and Davis DH. Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic J Neurosurg 98:1247-1254.
19. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL and Suchowersky O. 2002. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2003; 17:1288-1293.
20. Tsui JK. Botulinum toxin as a therapeutic agent. Pharmacol Ther 1996; 72:13-24.
21. Calace P, Cortese G, Piscopo R, Della VG, V Gagliardi, Magli A, and De Berardinis T. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results Eur J Ophthalmol 2003; 13: 331-336.
22. Glass M and Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997; 17:5327-5333.
23. Meschler JP and Hewlett AC. Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 2001; 40:918-926.
24. Iversen L. Cannabis and the brain Brain 126:1252-1270.
25. Muller-Vahl KR, Kolbe H, Schneider U and Emrich HM. Cannabis in movement disorders. Forsch Komplementaermed 1999; 6 (Suppl 3):23-27.
26. Calignano A, La Rana G, Giuffrida A and Piomelli D. Control of pain initiation by endogenous cannabinoids Nature 1998; 394: 277-281.
27. Malan TP, Ibrahim MM, Vanderah TW, Makriyannis A, and Porreca F. Inhibition of pain responses by activation of CB(2) cannabinoid receptors. Chem Phys Lipids 2002; 121:191-200.
28. Walker JM, Huang SM, Strangman NM, Tsou K and Sanudo-Pena MC. Pain modulation by release of the endogenous cannabinoid anandamide. PNAS 1999; 96:12198-12203.
29. Muller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T and Emrich HM. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002; 35:57-61.
30. Moss DE, Manderscheid PZ, Montgomery SP, Norman AB and Sanberg PR. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci 1989; 44:1521-1525.
31. Muller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM and Schneider U. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 2003; 28: 384-388.
32. Christopoulos A and Wilson K. Interaction of anandamide with the M-1 and M-4 muscarinic acetylcholine receptors. Brain Research 2001; 915:70.
33. Gifford AN, Tang Y, Gatley SJ, Volkow ND, Lan R and Makriyannis A. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neurosci Lett 1997; 238:84-86.
34. Katona I, Sperlagh B, Magloczky Z, Santha E, Kofalvi A, Czirjak S, Mackie K, Vizi ES and Freund TF. Gabaergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 2000; 100:797-804.
35. Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95:165-174.
36. Smith PF. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. Curr Opin Investig Drugs 2002; 3:859-864.